ADMA Biologics Raises Full-year Revenue Outlook

(RTTNews) - ADMA Biologics, Inc. (ADMA) Monday announced preliminary revenue for fiscal 2024 of between $417 million and 425 million, up from the previous guidance of $415 million.

Analysts on average expect revenue of $423.19 million for the year.

Looking ahead to 2025, the company sees revenue to exceed $485 million. Net income for the year is expected to be more than $170 million and adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization to be above $220 million.

By 20230, the company expects to generate more than $1 billion in annual revenue.